title: [Evaluation before and after pranlukast administration with the QOL questionnaire (revised version 2001) for pediatric patients with bronchial asthma and their parents or caregivers].
abstract: We conducted a longitudinal investigation with the QOL questionnaire (revised version 2001) before and after the 4-week-administration of a leukotriene receptor antagonist pranlukast. A significant improvement in the < 4 yrs group was observed at week 1, and that in > or = 4 yrs group at week 2. Under these conditions, the overall QOL score, physical domains and mental domains, significantly improved in both the < 4 yrs group and the > or = 4 yrs group. Overall, a slight correlation was observed between ratio changes in QOL scores and differences in symptom scores. However, no correlation was found in part of patients, suggesting that the QOL questionnaire allows measurement of mental changes in the patients themselves and their parents or caregivers for therapeutic effects which cannot be determined with ordinary physical findings only. In "event present" group, a significant difference in physical and mental domains was revealed by the comparison of QOL scores before and after administration. And furthermore in "event absence" group, the p-value for physical domain and mental domain was 0.0505 and 0.0912 in the < 4 yrs group, respectively, 0.0101 and 0.0446 in the > or = 4 yrs group, respectively. The above results led us to consider the QOL questionnaire (revised version 2001) useful for routine medical care. Furthermore, pranlukast was considered useful for improvement not only of physical symptoms of bronchial asthma but also of the patient's QOL, although the placebo effects in this open trial must be considered.
authors.affiliation: Department of Pediatrics, Gifu University School of Medicine.
authors.forename: Naomi
authors.initials: N
authors.lastname: Kondo
authors.forename: Takahide
authors.initials: T
authors.lastname: Teramoto
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Inoue
authors.forename: Osamu
authors.initials: O
authors.lastname: Fukutomi
authors.forename: Eiko
authors.initials: E
authors.lastname: Matsui
authors.forename: Shinji
authors.initials: S
authors.lastname: Shinoda
authors.forename: Mizuho
authors.initials: M
authors.lastname: Watanabe
authors.forename: Heima
authors.initials: H
authors.lastname: Sakaguchi
authors.forename: Minako
authors.initials: M
authors.lastname: Aoki
authors.forename: Wataru
authors.initials: W
authors.lastname: Morimoto
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Suzuki
authors.forename: Hidenori
authors.initials: H
authors.lastname: Ohnishi
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Takemoto
authors.forename: Yoko
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Asano
authors.forename: Kaori
authors.initials: K
authors.lastname: Yoshikawa
authors.forename: Tomoko
authors.initials: T
authors.lastname: Nagase
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Fujita
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Airen
authors.initials: A
authors.lastname: Ri
authors.forename: Khoichirou
authors.initials: K
authors.lastname: Hirayama
mesh_terms: D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D002675:Child, Preschool; D002867:Chromones / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D011788:Quality of Life; D011795:Surveys and Questionnaires
chemical_list: D018927:Anti-Asthmatic Agents; D002867:Chromones; D020024:Leukotriene Antagonists; C047681:pranlukast